Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SGPL1 | O95470 | 6/20 | 0.47 |
| ▸ | CTSA | P10619 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700835 | 0.88 | SGPL1 (0.49) | MEN1KMT2ASGPL1CYP1A2CYP2C19 | |
| SCHEMBL5700842 | 0.88 | SGPL1 (0.49) | MEN1KMT2ASGPL1CYP1A2CYP2C19 | |
| SCHEMBL4033089 | 0.84 | SGPL1 (0.44) | CYP26A1MEN1KMT2ASGPL1CYP1A2 | |
| SCHEMBL27577535 | 0.81 | MMEL1 (0.48) | MEN1KMT2ACTSACYP1A2CYP2D6 | |
| SCHEMBL8266861 | 0.72 | NPC1 (0.77) | MEN1KMT2A | |
| SCHEMBL7664361 | 0.71 | CYP1A2 (0.74) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9830762 | 0.71 | KDM4E (0.55) | MEN1KMT2ACTSA | |
| SCHEMBL5927099 | 0.70 | CTSA (0.69) | CTSA | |
| SCHEMBL1106963 | 0.69 | MAPT (0.73) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2827515 | 0.69 | MAPT (0.65) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177186-B1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-6620832-B2 | Inhibitor of alpha 4 beta 1 mediated cell adhesion; treatment for asthma and antiinflammatory | AVENTIS PHARMA LTD. (GB) | 2003-09-16 | — | — | US | disclosed |
| US-20020082255-A1 | Substituted ureas | AVENTIS PHARMA LIMITED (GB) | 2002-06-27 | — | — | US | disclosed |
| EP-1177186-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | Aventis Pharma Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068223-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082255-A1 | Substituted ureas | VCAM1, ITGA1, ITGB1 | CYP26A1 423/4885MEN1 4557/4885KMT2A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.